INVIVYD INC.

NASDAQ: IVVD (Invivyd, Inc.)

最近更新时间: 昨天, 11:54AM

2.35

0.58 (32.77%)

前收盘价格 1.77
收盘价格 2.56
成交量 135,783,766
平均成交量 (3个月) 9,955,126
市值 547,838,656
预期市盈率 (P/E Forward) 19.68
价格/销量 (P/S) 4.69
股市价格/股市净资产 (P/B) 4.43
52周波幅
0.355 (-84%) — 2.76 (17%)
利润日期 6 Nov 2025
营业利益率 (TTM) -149.70%
稀释每股收益 (EPS TTM) -1.19
总债务/股东权益 (D/E MRQ) 1.65%
流动比率 (MRQ) 1.53
营业现金流 (OCF TTM) -141.41 M
杠杆自由现金流 (LFCF TTM) -65.66 M
资产报酬率 (ROA TTM) -57.84%
股东权益报酬率 (ROE TTM) -122.69%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Invivyd, Inc. 看涨 看涨

AIStockmoo 评分

-1.0
分析师共识 1.5
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 -2.5
技术振荡指标 2.0
平均 -1.00

相关股票

股票 市值 DY P/E(TTM) P/B
IVVD 548 M - - 4.43
MRNA 10 B - - 1.12
COGT 5 B - - 25.80
HRMY 2 B - 10.74 2.31
ORIC 1 B - - 3.65
NKTR 1 B - - 13.87

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 41.18%
机构持股比例 66.10%
52周波幅
0.355 (-84%) — 2.76 (17%)
目标价格波幅
2.00 (-14%) — 10.00 (325%)
10.00 (Cantor Fitzgerald, 325.53%) 购买
10.00 (HC Wainwright & Co., 325.53%) 购买
10.00 (325.53%)
2.00 (D. Boral Capital, -14.89%) 购买
平均值 7.33 (211.92%)
总计 3 购买
平均价格@调整类型 1.48
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 03 Nov 2025 10.00 (325.53%) 购买 1.61
31 Oct 2025 10.00 (325.53%) 购买 1.76
Cantor Fitzgerald 06 Oct 2025 10.00 (325.53%) 购买 1.42
D. Boral Capital 06 Oct 2025 2.00 (-14.89%) 购买 1.42
25 Aug 2025 1.00 (-57.45%) 购买 0.560

该时间范围内无数据。

日期 类型 细节
06 Nov 2025 公告 Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
03 Nov 2025 公告 Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
28 Oct 2025 公告 Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
06 Oct 2025 公告 Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
24 Sep 2025 公告 Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
17 Sep 2025 公告 Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
04 Sep 2025 公告 SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
27 Aug 2025 公告 Invivyd to Participate in Upcoming Investor Conferences
22 Aug 2025 公告 Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
20 Aug 2025 公告 Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
20 Aug 2025 公告 Invivyd Announces Proposed Public Offering of Common Stock
18 Aug 2025 公告 Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票